Socioeconomic Factors Affect Treatment Selection, Outcomes in Early-Stage Hodgkin Lymphoma

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the Journal of Clinical Oncology, researchers from The Cancer Center at Memorial Hospital of Rhode Island in Pawtucket, Rhode Island, have found that socioeconomic factors affect selection of curative treatments in Hodgkin lymphoma.

For the study, researchers sought to identify factors affecting treatment selection and resulting survival outcomes in patients with early-stage Hodgkin lymphoma in the United States. Researchers identified 20,600 patients treated with combined-modality therapy or chemotherapy between 2003 and 2011 from the National Cancer Data Base.

Results showed that only 49.5% of those treated between 2003 and 2011 received combined-modality therapy. This proportion was found to have steadily declined, particularly in younger patients. Researchers found that treatment selection was significantly influenced by black race, sex, distance to facility, and type of insurance. 

Those who were uninsured were least likely to receive combined-modality therapy. Combined-modality therapy was found to be associated with better overall survival and relative survival compared with chemotherapy alone.

The findings suggest that socioeconomic factors affect selection of curative treatment approaches in patients with Hodgkin lymphoma, thereby possibly affect survival of these patients.

The authors note that strategies should be developed to minimize toxicity and access disparities without diminishing survival.

How frequent are mutations in known breast cancer predisposition genes in women with TNBC who were u
Socioeconomic factors affect selection of curative treatments in Hodgkin lymphoma.
The objective was to define factors affecting treatment selection and resulting survival outcomes in the United States. Socioeconomic factors affect selection of curative treatments in HL. Widespread abandonment of CMT beyond circumstances sanctioned by guidelines may affect survival.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs